ZLAB•benzinga•
China's National Medical Products Administration Accepts Zai Lab's New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga